Company Overview of BioArctic Neuroscience AB
BioArctic Neuroscience AB develops immunotherapeutic treatments for neurodegenerative diseases. It provides BAN2401, a technology platform that is used to isolate various proteins implicated in CNS disorders and study their aggregation properties, prepare and stabilize protofibrils, and develop protofibril specific monoclonal antibodies. The company offers treatments for people suffering from Alzheimer’s, Parkinson’s, ALS, Huntington’s, and Creutzfeldt-Jacob’s diseases. BioArctic Neuroscience AB was founded in 2003 and is based in Stockholm, Sweden.
Warfvinges väg 39
Stockholm, 112 51
Founded in 2003
46 86 95 69 30
46 86 95 69 39
Key Executives for BioArctic Neuroscience AB
Similar Private Companies By Industry
|Archaea Pharma AB||Europe|
|Athera Biotechnologies AB||Europe|
|Plant Science Sweden AB||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact BioArctic Neuroscience AB, please visit www.bioarctic.se. Company data is provided by Capital IQ. Please use this form to report any data issues.